Search

Search Results

1. Terapia del carcinoma corticosurrenalico dopo fallimento del mitotane

   Mitotane is the only approved drug in the management of adrenocortical carcinoma (ACC). Mitotane can be administered in the adjuvant setting in...

   Salvatore Grisanti, Valentina Cremaschi, Alfredo Berruti in L'Endocrinologo

   Article Open access 19 September 2023
   

2. Mitotane

   in Reactions Weekly

   Article 08 June 2024

3. Dexamethasone/Mitotane

   in Reactions Weekly

   Article 20 April 2024

4. Mitotane

   in Reactions Weekly

   Article 04 March 2023

5. EDP-mitotane in children: reassuring evidence of reversible side-effects and neurotoxicity

   Adrenocortical carcinoma affects one in 5 million children each year. Since prognosis for children older than 4 years is limited, clinicians often...

   Rebecca V. Steenaard, Marieke Rutjens, ... Harm R. Haak in Discover Oncology

   Article Open access 18 April 2022
   

6. Mitotane

   in Reactions Weekly

   Article 07 January 2023

7. Mitotane

   in Reactions Weekly

   Article 04 June 2022

8. Mitotane

   in Reactions Weekly

   Article 26 March 2022

9. Cisplatin/etoposide/mitotane

   in Reactions Weekly

   Article 30 April 2022

10. Valutazione dell’efficacia della terapia adiuvante con mitotane nel carcinoma corticosurrenalico localizzato con rischio di recidiva basso-moderato (Studio ADIUVO)

    Chiara Vitiello, Concita Trischitta, ... Maria Cristina De Martino in L'Endocrinologo

    Article 09 November 2023

11. Mitotane With or Without Cisplatin and Etoposide for Patients with a High Risk of Recurrence in Stages 1–3 Adrenocortical Cancer After Surgery

    Amber Leila Sarvestani, Stephanie N. Gregory, ... Mouhammed Amir Habra in Annals of Surgical Oncology

    Article 28 October 2022
    

12. Mitotane

    in Reactions Weekly

    Article 08 May 2021

13. Clinical management and outcomes associated with etoposide, doxorubicin, and cisplatin plus mitotane treatment in metastatic adrenocortical carcinoma: a single institute experience

    Background

    Adrenocortical carcinoma (ACC) is a rare and aggressive disease that is often diagnosed at an advanced stage. There is no standard...

    Masaki Uchihara, Maki Tanioka, ... Kan Yonemori in International Journal of Clinical Oncology

    Article 01 September 2021
    

14. Oncocytic adrenocortical neoplasm of borderline uncertain malignant potential diagnosed after robot-assisted adrenalectomy case report

    Background

    Adrenal incidentalomas are radiologically discovered tumors that represent a variety of pathologies, with the diagnosis clinched only on...

    Chih Peng Chin, Ralph Grauer, ... Ketan K. Badani in BMC Urology

    Article Open access 15 April 2023
    

15. Massive adrenocortical carcinoma presenting as peripheral edema: a case report

    Background

    Adrenocortical carcinoma is a rare, but potentially lethal, malignancy that is usually detected as an incidental finding on abdominal...

    David A. Goodkin in Journal of Medical Case Reports

    Article Open access 20 June 2022
    

16. Mitotane

    in Reactions Weekly

    Article 20 June 2020

17. Pregnancy in patients with adrenocortical carcinoma: a case-based discussion

    Although adrenocortical carcinoma (ACC) during pregnancy is rare, a retrospective review of a case series at our hospital revealed that almost one...

    Soraya Puglisi, Vittoria Basile, ... Massimo Terzolo in Reviews in Endocrine and Metabolic Disorders

    Article 22 November 2022
    

18. Different management of adrenocortical carcinoma in children compared to adults: is it time to share guidelines?

    Pediatric and adult adrenocortical carcinomas differ in many respects but treatment is often similar in both age groups. The Journal of Clinical...

    Salvatore Grisanti, Deborah Cosentini, ... Alfredo Berruti in Endocrine

    Article Open access 24 September 2021

19. Defining Optimal Management of Non-metastatic Adrenocortical Carcinoma

    Background

    Adrenocortical carcinoma (ACC) is an aggressive, deadly malignancy. Resection remains the primary treatment; however, there is conflicting...

    Jesse E. Passman, Wajid Amjad, ... Heather Wachtel in Annals of Surgical Oncology

    Article 05 November 2023
    

20. Mitotane (Lysodren®) in der Therapie des Nebennierenrindenkarzinoms

    Mitotane, or o,p’-DDD (European tradename: Lysodren®, HRA Pharma, Paris, France), is an orphan drug for the adjuvant therapy of adrenocortical...

    Wolfgang Raber in Journal für Klinische Endokrinologie und Stoffwechsel

    Article Open access 12 August 2019